Biotech stocks crumbled last year, and many prominent hedge funds have suffered deep losses. But some biotech investors are thriving by focusing on mergers, short selling, and Covid-19 stocks. Some analysts and investors say these three strategies will prove successful for biotech investors once again in 2022 (please see the article" In a Bad Year for Biotech Stocks, Deals and Vaccines Were Winners" under the reading folder).

What factors are expected to drive M&A in the biotech space? Which segment of the biotech sector performed well in 2021? Do you think Biotech stocks will be a good investment in 2022? Please discuss.

Answer rating: 100% (QA)

Factors expected to drive MA in the biotech space One of the key factors driving MA activity in the biotech sector is the need for companies to bolste... View the full answer